Cochlear Limited
Cochlear Limited (CHEOF) Financial Performance & Income Statement Overview
Explore the financials of Cochlear Limited (CHEOF), including yearly and quarterly data on income, cash flow, and balance sheets.
Cochlear Limited (CHEOF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Cochlear Limited CHEOF financial performance.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $1.17B | $1.14B | $1.11B | $1.06B |
| Cost of Revenue | $297.50M | $276.30M | $285.80M | $261.10M |
| Gross Profit | $874.30M | $868.50M | $827.60M | $802.00M |
| Gross Profit Ratio | $0.75 | $0.76 | $0.74 | $0.75 |
| R&D Expenses | $144.40M | $149.70M | $127.30M | $142.30M |
| SG&A Expenses | $470.00M | $465.60M | $432.00M | $441.50M |
| Operating Expenses | $599.70M | $615.30M | $559.30M | $583.80M |
| Total Costs & Expenses | $897.20M | $891.60M | $845.10M | $844.90M |
| Interest Income | $0.00 | $0.00 | $9.40M | $9.80M |
| Interest Expense | $0.00 | $0.00 | $4.30M | $4.70M |
| Depreciation & Amortization | $43.80M | $41.80M | $43.10M | $43.60M |
| EBITDA | $315.60M | $271.70M | $307.80M | $261.80M |
| EBITDA Ratio | $0.27 | $0.24 | $0.28 | $0.25 |
| Operating Income | $274.60M | $253.20M | $268.30M | $218.20M |
| Operating Income Ratio | $0.23 | $0.22 | $0.24 | $0.21 |
| Other Income/Expenses (Net) | $2.10M | -$28.20M | $5.10M | -$9.30M |
| Income Before Tax | $276.70M | $225.00M | $260.40M | $209.10M |
| Income Before Tax Ratio | $0.24 | $0.20 | $0.23 | $0.20 |
| Income Tax Expense | $71.20M | $59.40M | $68.60M | $49.90M |
| Net Income | $205.10M | $165.40M | $191.40M | $159.00M |
| Net Income Ratio | $0.18 | $0.14 | $0.17 | $0.15 |
| EPS | $3.12 | $2.53 | $2.92 | $2.42 |
| Diluted EPS | $3.13 | $2.52 | $2.91 | $2.41 |
| Weighted Avg Shares Outstanding | $65.62M | $65.49M | $65.58M | $65.67M |
| Weighted Avg Shares Outstanding (Diluted) | $65.62M | $65.73M | $65.71M | $66.002M |
Over the past four quarters, Cochlear Limited demonstrated steady revenue growth, increasing from $1.06B in Q4 2023 to $1.17B in Q2 2025. Operating income reached $274.60M in Q2 2025, maintaining a consistent 23% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $315.60M, reflecting operational efficiency. Net income rose to $205.10M, with EPS at $3.12. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan